diff --git a/domains/entertainment/youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md b/domains/entertainment/youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md index 8f4aa796..a7137d03 100644 --- a/domains/entertainment/youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md +++ b/domains/entertainment/youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md @@ -35,6 +35,12 @@ This is one data point from one studio. The claim is experimental because it's b The Claynosaurz-Mediawan co-production will launch on YouTube first, then sell to TV and streaming buyers. This inverts the traditional risk model: YouTube launch proves audience metrics before traditional buyers commit, using the community's existing social reach (~1B views) as a guaranteed launch audience. Mediawan brings professional production quality while the community provides distribution validation, creating a new risk-sharing structure where platform distribution precedes rather than follows traditional media deals. + +### Additional Evidence (extend) +*Source: [[2025-02-01-deadline-pudgy-penguins-youtube-series]] | Added: 2026-03-16* + +Pudgy Penguins chose to launch Lil Pudgys on its own YouTube channel (13K subscribers) rather than leveraging TheSoul Publishing's 2B+ follower distribution network. This extends the claim by showing that YouTube-first distribution can mean building a DEDICATED brand channel rather than parasitizing existing platform reach. The decision prioritizes brand ownership over reach maximization, suggesting YouTube-first is not just about platform primacy but about audience ownership architecture. + --- Relevant Notes: diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2220e30b..377f3150 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -71,6 +71,12 @@ The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE hea WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems. + +### Additional Evidence (challenge) +*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* + +Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 3d9ef0bb..518add3b 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -59,6 +59,12 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2 The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. + +### Additional Evidence (extend) +*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* + +Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json b/inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json new file mode 100644 index 00000000..a7b5bf86 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json @@ -0,0 +1,26 @@ +{ + "rejected_claims": [ + { + "filename": "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 3, + "rejected": 1, + "fixes_applied": [ + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:set_created:2026-03-16", + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d", + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category" + ], + "rejections": [ + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md b/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md index 9ff56b5e..348224d6 100644 --- a/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md +++ b/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md @@ -7,9 +7,13 @@ date: 2025-01-01 domain: health secondary_domains: [] format: study -status: unprocessed +status: enrichment priority: high tags: [glp-1, adherence, digital-health, weight-loss, tirzepatide, behavioral-support, obesity] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -60,3 +64,12 @@ A retrospective cohort service evaluation study published in the Journal of Medi PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: Convergent evidence that digital behavioral support partially solves the GLP-1 adherence problem — changes the economic model under capitation if sustained EXTRACTION HINT: Focus on the half-dose finding (cost efficiency) and the convergence with WHO guidelines (behavioral combination is now international standard). Scope carefully — observational, not RCT. + + +## Key Facts +- Voy platform components include live group video coaching, text-based support, educational content, weight monitoring, and adherence tracking +- UK Voy study showed high withdrawal rate in non-engaged group limiting generalizability +- Tirzepatide users outperformed semaglutide users: 13.9% vs 9.5% at 5 months in Voy cohort +- WHO December 2025 guidelines recommend combining GLP-1 with intensive behavioral therapy +- Danish study was 64 weeks duration, UK Voy study was 5 months +- All three studies (UK, Danish, Wiley) were retrospective/observational, not RCTs diff --git a/inbox/archive/2025-02-01-deadline-pudgy-penguins-youtube-series.md b/inbox/archive/2025-02-01-deadline-pudgy-penguins-youtube-series.md index 8940fc62..c0ffc66b 100644 --- a/inbox/archive/2025-02-01-deadline-pudgy-penguins-youtube-series.md +++ b/inbox/archive/2025-02-01-deadline-pudgy-penguins-youtube-series.md @@ -7,9 +7,13 @@ date: 2025-02-01 domain: entertainment secondary_domains: [internet-finance] format: article -status: unprocessed +status: enrichment priority: medium tags: [pudgy-penguins, lil-pudgys, youtube, animated-series, thesoul-publishing, community-ip-distribution] +processed_by: clay +processed_date: 2026-03-16 +enrichments_applied: ["youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,12 @@ PRIMARY CONNECTION: [[entertainment IP should be treated as a multi-sided platfo WHY ARCHIVED: Secondary source confirming Lil Pudgys launch details; the 13K→millions trajectory data point. EXTRACTION HINT: Use as supplementary evidence. The primary archive for the Lil Pudgys quality tension is `2025-02-01-animation-magazine-lil-pudgys-launch-thesoul.md`. + + +## Key Facts +- Pudgy Penguins YouTube channel had 13,000 subscribers at Lil Pudgys series launch (Spring 2025) +- Lil Pudgys series: 1,000+ minutes of animation, 5-minute episodes, 2/week release cadence +- TheSoul Publishing: 2B+ social media followers, known for 5-Minute Crafts +- Pudgy Penguins retail metrics at announcement: $10M+ toy sales, 2M+ units, 3,100+ Walmart stores, 7,000+ retail locations +- Pudgy Penguins GIPHY views surpassing Hello Kitty and Pokémon (50B+ by announcement date) +- By 2026, Lil Pudgys episodes garnering millions of views per episode (per DappRadar)